Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes José H. VoldersVera L. NegenbornM. Petrousjka van den Tol Review Open access 06 December 2017 Pages: 1 - 12
Correction to: Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes José H. VoldersVera L. NegenbornM. Petrousjka van den Tol Correction 11 January 2018 Pages: 13 - 15
Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer Josefine BostnerAnya AlayevOlle Stål Preclinical study Open access 11 November 2017 Pages: 17 - 27
Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results Kamaljeet SinghXin HeC. James Sung Preclinical study 11 December 2017 Pages: 29 - 34
Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials Filipa LynceMatthew J. BlackburnPaula R. Pohlmann Clinical trial 08 November 2017 Pages: 35 - 41
Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer K. A. NyropA. M. DealH. B. Muss Clinical trial 09 November 2017 Pages: 43 - 55
Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer Maryann KwaXiaochun LiSylvia Adams Clinical trial 09 November 2017 Pages: 57 - 67
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology Eleftherios P. MamounasGong TangNorman Wolmark Clinical trial 11 November 2017 Pages: 69 - 77
Adding high-intensity interval training to conventional training modalities: optimizing health-related outcomes during chemotherapy for breast cancer: the OptiTrain randomized controlled trial Sara MijwelMalin BackmanYvonne Wengström Clinical trial Open access 14 November 2017 Pages: 79 - 93
Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer Hánah N. RierAgnes JagerMark-David Levin Clinical trial 17 November 2017 Pages: 95 - 105
Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up Karama AslehJennifer R. WonTorsten O. Nielsen Clinical trial 20 November 2017 Pages: 107 - 115
BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer Martin P. NilssonTherese TörngrenNiklas Loman Clinical trial Open access 21 November 2017 Pages: 117 - 126
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial Joyce O’ShaughnessyKatarina PetrakovaGabriel N. Hortobagyi Clinical trial Open access 21 November 2017 Pages: 127 - 134
Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers Takahiro WatanabeAkira I. HidaYasuo Miyoshi Clinical trial 22 November 2017 Pages: 135 - 145
Adipose tissue inflammation in breast cancer survivors: effects of a 16-week combined aerobic and resistance exercise training intervention Christina M. Dieli-ConwrightJean-Hugues ParmentierSteven D. Mittelman Clinical trial 22 November 2017 Pages: 147 - 157
Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer Rossanna C. PezoTom W. ChenPhilippe L. Bedard Clinical trial Open access 24 November 2017 Pages: 159 - 168
Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES M. C. U. CheangJ. M. BlissOn Behalf of the PathIES Sub-Committee Clinical trial Open access 24 November 2017 Pages: 169 - 178
Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer S. L. VillegasS. Darb-EsfahaniS. Loibl Clinical trial 25 November 2017 Pages: 179 - 187
Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study O. BrouckaertK. Van AstenOn behalf of Multidisciplinary breast centre Leuven Epidemiology 20 November 2017 Pages: 189 - 196
Real-world treatment in patients with HER2+ metastatic breast cancer R. ColomerP. HallJ. Y. Le Cléac’h Epidemiology Open access 23 November 2017 Pages: 197 - 205
Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results David J. PressAbiola IbraheemDezheng Huo Epidemiology 27 November 2017 Pages: 207 - 220
Willingness of breast cancer patients to undergo biopsy and breast cancer clinicians’ practices around seeking biopsy at the time of breast cancer relapse Caroline LohrischMia FranclKaren A. Gelmon Epidemiology 27 November 2017 Pages: 221 - 228
Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening Amy Trentham-DietzMehmet Ali ErgunBrian L. Sprague Epidemiology 28 November 2017 Pages: 229 - 239
Body mass index, diet, and exercise: testing possible linkages to breast cancer risk via DNA methylation Arielle S. GillmanCasey K. GardinerAngela D. Bryan Brief Report 10 November 2017 Pages: 241 - 248
Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer Andrew DodsonDavid OkonjiMitch Dowsett Brief Report Open access 11 November 2017 Pages: 249 - 258
Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot Karen MenesesRachel BenzDavid E. Vance Brief Report Open access 11 November 2017 Pages: 259 - 267
Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting Omar Abdel-Rahman Brief Report 15 November 2017 Pages: 269 - 275
Are VNTRs co-localizing with breast cancer-associated SNPs? Martin LeclercSusan L. NeuhausenEitan Friedman Brief Report 22 November 2017 Pages: 277 - 281
Does tacrolimus have any positive impact on outcome of post-transplant breast cancer patients? Kadri Altundag Letter to the Editor 24 November 2017 Pages: 283 - 283
Obesity’s impact on survival is independent of dose adjustments in neoadjuvant chemotherapy in women with breast cancer Ying L. LiuEileen P. ConnollyKevin Kalinsky Letter to the Editor 24 November 2017 Pages: 285 - 285
